Quazepam, a Sedative‐Hypnotic Selective for the Benzodiazepine Type 1 Receptor: Autoradiographic Localization in Rat and Human Brain

@article{Wamsley1985QuazepamAS,
  title={Quazepam, a Sedative‐Hypnotic Selective for the Benzodiazepine Type 1 Receptor: Autoradiographic Localization in Rat and Human Brain},
  author={James K. Wamsley and Joshua S. Golden and Henry I. Yamamura and Allen Barnett},
  journal={Clinical Neuropharmacology},
  year={1985},
  volume={8},
  pages={S26–S40}
}
Journal issues prior to the current volume, when available, may be ordered at the single issue rate. Air delivery included for European and Mediterranean countries; for air delivery elsewhere, add $21. Payments should accompany all orders. Please enclose present mailing label with all change of address requests. 
Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia.
TLDR
Preliminary evidence suggests that quazepam 15 to 30 mg is as effective as flurAZepam and triazolam in usual therapeutic doses, and causes minimal rebound insomnia following its withdrawal, unlike rapidly eliminated benzodiazepines such as triazlam.
A Guide to Benzodiazepine Selection. Part I: Pharmacological Aspects*
  • E. Teboul, G. Chouinard
  • Biology, Psychology
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 1990
TLDR
With repeated use, sedation and cognitive neuromotor impairment usually diminish progressively despite stable or even rising benzodiazepine plasma concentrations, whereas anxiolytic effects generally persist over time.
Enhancement of γ‐Aminobutyric Acid Binding by Quazepam, a Benzodiazepine Derivative with Preferential Affinity for Type I Benzodiazepine Receptors
TLDR
The [3H]GABA binding‐enhancing effect of quazepam was mediated by an occupancy of benzodiazepine receptors, because it was specifically antagonized by 5 × 10−‐6M Ro15–1788.